Tienhaara A, Pulkki K, Mattila K, Irjala K, Pelliniemi T T
Department of Haematology, Turku University Central Hospital, Finland.
Br J Haematol. 1994 Feb;86(2):391-3. doi: 10.1111/j.1365-2141.1994.tb04748.x.
Serum bioactive but not immunoreactive interleukin-6 (IL-6), and serum C-reactive protein (CRP), have been reported to be of prognostic significance in multiple myeloma (MM). We measured serum immunoreactive IL-6 by a sensitive enzyme-linked immunosorbent assay in 30 MM patients at diagnosis. In 30% of the patients serum immunoreactive IL-6 exceeded the upper reference limit. The concentrations of CRP and IL-6 showed a linear association. Logarithmically transformed IL-6, CRP and beta 2-microglobulin were significant variables by univariate survival analysis; by multivariate analysis CRP was a slightly stronger prognostic factor than IL-6 and the only one of independent prognostic significance.
据报道，血清生物活性而非免疫反应性白细胞介素-6（IL-6）以及血清C反应蛋白（CRP）在多发性骨髓瘤（MM）中具有预后意义。我们采用灵敏的酶联免疫吸附测定法，对30例MM患者诊断时的血清免疫反应性IL-6进行了检测。30%的患者血清免疫反应性IL-6超过参考上限。CRP和IL-6的浓度呈线性相关。单因素生存分析显示，经对数转换的IL-6、CRP和β2-微球蛋白是显著变量；多因素分析表明，CRP作为预后因素比IL-6略强，且是唯一具有独立预后意义的因素。
